News

"Asia-Pacific is poised to become the world’s next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines," said Senior Vice President Ross

Aubagio is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. "Aubagio is proving

"While we are disappointed by the Court’s decision to uphold this ruling, we intend to continue our strong efforts to convey the significant benefits of NAMENDA XR to

The study, called SARIL-RA-TARGET, evaluated the efficacy and safety of two subcutaneous sarilumab doses versus placebo, added to non-biologic disease modifying anti-rheumatic drugs (DMARD) therapy in RA patients

The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to

Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was based on events of suicidal ideation

Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol

Aptensio XR is an extended-release formulation of methylphenidate capsule with an onset of effect of one hour and 12-hour duration of effect with about 40% of the active

A total of 2,157 patients with AHF were enrolled in the trial from over 200 centers across the US, Europe, Canada and Latin America. The TRUE-AHF Phase III